Skip to main content
. 2016 Oct 14;6:35173. doi: 10.1038/srep35173

Figure 2. Th1-type antibody production by aAVC-OVA vaccination in a CD4+ T cell-dependent manner.

Figure 2

(a,b) Serum anti-OVA antibody isotype at 2 weeks after immunization with alum plus OVA protein (0.1 or 100 μg) i.p., 500 ng α-GalCer plus OVA (0.1 μg) i.p. or aAVC-OVA (0.1 μg OVA protein-containing NIH3T3) i.v. (Mean±SEM, n = 4–5) *P < 0.05, ***P < 0.001. (aAVC-OVA vs others) (c) OVA-specific serum IgG1 and IgG2b antibody response were measured in WT mice and CD4−/− mice 2 weeks after immunization with aAVC-OVA. (Mean±SEM, n = 9–12) *P < 0.05, ***P < 0.001.